Literature DB >> 26036898

Shifting paradigms in diminished ovarian reserve and advanced reproductive age in assisted reproduction: customization instead of conformity.

Beverly G Reed1, Samir N Babayev1, Orhan Bukulmez1.   

Abstract

As women are increasingly delaying childbearing into their 30s and beyond, diminished ovarian reserve (DOR) and advanced reproductive age (ARA) patients are bound to become a large proportion of all assisted reproductive technology practices. Traditional controlled ovarian stimulation (COS) protocols for DOR and/or ARA have had some limited success, but pregnancy rates are lower and cycle cancellation rates are higher than their younger counterparts with normal ovarian reserve. Though many physicians have a selection of favorite standard protocols that they use, patients with DOR may require closer monitoring and customization of the treatment cycle to address the common problems that come with low ovarian reserve. Frequent issues that surface in women with DOR and/or ARA include poor follicular response, premature luteinizing hormone surge, and poor embryo quality. Limited published evidence exists to guide treatment for DOR. However, use of minimal or mild doses of gonadotropins, avoidance of severe pituitary suppression, and consideration for luteal phase stimulation and a "freeze all" approach are possible customized treatment options that can be considered for such patients who have failed more traditional COS protocols. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26036898     DOI: 10.1055/s-0035-1552585

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  7 in total

1.  Prediction of live birth and cumulative live birth rates in freeze-all-IVF treatment of a general population.

Authors:  Kemal Ozgur; Hasan Bulut; Murat Berkkanoglu; Levent Donmez; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2019-02-21       Impact factor: 3.412

2.  Embryo Banking with Mild Ovarian Stimulation for IVF: An Alternative Strategy for Poor Prognosis Patients.

Authors:  Ivan Sini; Arie A Polim; Nining Handayani; Adinda Pratiwi; Rosalina Thuffi; Nuraeni Yusup; Arief Boediono
Journal:  J Reprod Infertil       Date:  2020 Jul-Sep

3.  Controlled Ovarian Stimulation Protocols Alter Endometrial Histomorphology and Gene Expression Profiles.

Authors:  John L Wu; Patrick Keller; Mohammed Kanchwala; Chao Xing; Samir N Babayev; Bruce R Carr; Orhan Bukulmez; R Ann Word
Journal:  Reprod Sci       Date:  2020-01-06       Impact factor: 3.060

4.  Use of Clomiphene Citrate in minimal stimulation in vitro fertilization negatively impacts endometrial thickness: an argument for a freeze-all approach.

Authors:  Beverly G Reed; John L Wu; Laurice Bou Nemer; Bruce R Carr; Orhan Bukulmez
Journal:  JBRA Assist Reprod       Date:  2018-11-01

5.  Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study.

Authors:  Panagiotis Drakopoulos; Arne van de Vijver; Jose Parra; Ellen Anckaert; Johan Schiettecatte; Christophe Blockeel; Martin Hund; Wilma D J Verhagen-Kamerbeek; Ying He; Herman Tournaye; Nikolaos P Polyzos
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-26       Impact factor: 5.555

6.  Progestin-Primed Ovarian Stimulation Versus Mild Stimulation Protocol in Advanced Age Women With Diminished Ovarian Reserve Undergoing Their First In Vitro Fertilization Cycle: A Retrospective Cohort Study.

Authors:  Xiaoyu Tu; Bingbing You; Miaomiao Jing; Chenxi Lin; Runju Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-24       Impact factor: 5.555

7.  Human amnion-derived mesenchymal stem cells improved the reproductive function of age-related diminished ovarian reserve in mice through Ampk/FoxO3a signaling pathway.

Authors:  Hanwen Liu; Chunyan Jiang; Boya La; Meng Cao; Song Ning; Jing Zhou; Zhengjie Yan; Chuyu Li; Yugui Cui; Xiang Ma; Meilian Wang; Li Chen; Youjia Yu; Feng Chen; Yuexin Zhang; Huimin Wu; Jiayin Liu; Lianju Qin
Journal:  Stem Cell Res Ther       Date:  2021-06-02       Impact factor: 6.832

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.